A single pen covers a full month's dose! Eli Lilly launches Zepbound multi-dose injection pen starting at $299.

```

Eli Lilly launched a new formulation of its blockbuster weight-loss drug Zepbound on Monday. The new version uses a single pen, providing the full monthly dosage.

Self-paying patients can purchase this multi-dose device, called KwikPen, through the company’s direct-to-consumer website LillyDirect. The price starts at $299 per month for the lowest dose.

This injection pen may be more convenient for some patients, as it reduces the number of devices needed each month. Patients can complete four weekly Zepbound injections using one pen.

Currently, patients undergoing this treatment need to use a different single-dose auto-injector each week. Lilly also offers single-dose vials of Zepbound, which patients need to draw into a syringe and inject themselves.

As a result of this news, Lilly’s stock price rose more than 5% during trading on Monday.

Media reported that this launch comes as Lilly is working to solidify Zepbound’s early success. Since its launch at the end of 2023, demand for Zepbound has soared. LillyDirect has played a key role in driving Zepbound’s growth, and launching the new formulation on this platform may attract more patients.

Zepbound’s strong growth has helped Lilly seize much of the weight-loss drug market from rival Novo Nordisk. Company data from the fourth quarter showed Zepbound brought in $4.2 billion in U.S. revenue, up 122% year over year.

Lilly stated that the U.S. Food and Drug Administration has approved expanding Zepbound’s label indication to include the multi-dose device.

KwikPen has previously been used for other medications, such as Lilly’s popular diabetes drug Mounjaro.

Ilya Yuffa, Lilly’s Head of U.S. and Global Customer Capabilities, said in a statement:

“As part of our commitment to supporting people with obesity in managing their weight, we are introducing this new option, the Zepbound KwikPen. This device has been used for other Lilly medications globally and in the U.S., and has earned patients’ trust.”

Risk warning and disclaimerThe market is risky and investment requires caution. This article does not constitute personal investment advice and has not taken into account the specific investment goals, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific situation. Investing based on this is at your own risk. ```